Clinical trial
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast…
NCT00337103 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00337103 |
|---|---|
| Title | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes |
| Official title | A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Eribulin Mesylate, Capecitabine |
| Enrollment | 1,276 |
| Start date | Sep 20, 2006 |
| Primary completion | Mar 12, 2012 |
| Completion | Dec 11, 2017 |
| First posted | Jun 15, 2006 |
| Last update posted | Jun 18, 2020 |
| Countries | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel and 11 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: